PDCD1 and hepatocellular carcinoma: In recent years, immune checkpoint inhibitors such as anti-PD-1 or anti-PD-L1 become an alternative therapeutic choice for HCC treatment, however the majority of patients do not respond to them when use as single agent [11, 45].